Sanofi's Sarclisa is recommended by NICE

, which is based on the French drug Sanofi, has been actively recommended by the National Institutes of Health (NICE) for patients with multiple myeloma.It has been recommended that Sarclisa (isatuximab) be combined with pomalidomide and dexamethasone (pom-dex) in adult patients who have received three previous treatments and at least two previous therapies, including lysine and protease inhibitors.The recommendation is based on data from the ICARIA-MM trial, which demonstrated that Sarclisa plus pom-dex can reduce the risk of disease progress or death in adults by 40 percent.Compared to 6.5 months of pom-dex-only treatment, the treatment has the potential to extend the progress-free life to 11.5 months. Overall, Sarclisa showed no worsening of the disease for another five months.It was also found that adding Sarclisa to pom-dex had good tolerance and that the rate of treatment interruptions or fatal events did not increase compared to those observed in the pom-dex group.In the UK, about 5,700 people are diagnosed with multiple myeloma each year, and more than 3,000 deaths are linked to multiple myeloma. Patients often experience frequent relapses, and cancer can become resistant to many available treatments.Laura Kerby, chief executive of Myeloma UK, said: "In the advanced stages of the disease, there are limited treatments available to patients, which means it is vital to increase the choice of treatment pathways.added: "Getting a treatment that can provide extra precious months without worsening the disease makes people want people to spend more time with the people they love." ”（cyy123.com）